Quantcast

Latest Daiichi Sankyo Company Limited Stories

2014-03-31 08:28:47

First patient enrolled in largest planned phase 3 study evaluating a novel oral anticoagulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion PARSIPPANY, N.J., March 31, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has started enrolling patients into the ENSURE-AF multinational phase 3 study, which will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor...

2014-03-24 08:27:40

- Subgroup analyses of East Asian populations from two phase 3 studies, ENGAGE AF-TIMI 48 and Hokusai-VTE, showed consistent results compared to the global study populations from these trials(1,2,3,4) TOKYO, March 24, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) enrolled in two phase...

2014-03-19 00:22:17

TOKYO, March 19, 2014 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Company, Limited ("Daiichi Sankyo," President and CEO: Joji Nakayama) today announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds. The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related